Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

How Will the Trump Presidency Affect Pharmaceutical Marketing?



Among those in the industry who could be most affected are pharmaceutical marketers, whose job centers around direct-to-consumer (DTC) advertising for prescription drugs.

Share this!

November 30, 2016 | by Sarah Hand, M.Sc.

Donald Trump’s election win could have significant effects on the pharmaceutical industry, but whether these changes will be good or bad has yet to be seen. Among those in the industry who could be most affected are pharmaceutical marketers, whose job centers around direct-to-consumer (DTC) advertising for prescription drugs.

Recently, an article published on FiercePharma outlined some current pharmaceutical industry perspectives on what Trump’s presidency could have in store for drugmakers. The industry is currently benefitting from a consistent flow of US Food and Drug Administration (FDA) approvals, keeping pharmaceutical marketers busy with advertising the drugs to consumers.

“While pharmaceutical companies may have a wait-and-see approach in some areas, such as pending healthcare legislation, I just don’t see ad spending slowing,” Wendy Blackburn, executive VP at pharmaceutical marketing agency, Intouch Solutions, told FiercePharma. “It’s likely safe to say the general consensus is that Trump’s election is a positive for this industry.”

As long as the FDA continues to approve drugs at the rate its going, industry insiders like John Kamp, executive director at the Coalition for Healthcare Communication, believe that pharmaceutical ad spending should stay the same. However, Trump has announced that he plans to reform the FDA by cutting red tape and expediting the approval of potentially life-saving drugs.

“The only thing that would negatively affect spending is if Trump had Medicare negotiate directly on lowering drug prices,” Bob Ehrlich, chairman-CEO of DTC Perspectives, told FiercePharma. While Ehrlich admitted that this was a possibility, he believes that Trump may lean toward the pharmaceutical industry’s side of the drug pricing debate.

Historically, the pharmaceutical industry has been less-reactive to changes in government compared to other sectors which rely on consumer marketing. This wait-and-see approach is leading many in the industry to hold their speculations until the president-elect takes office next year.

Keywords: Pharmaceutical Marketing, Pharmaceutical Industry, DTC Advertising


Share this with your colleagues!

Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News

FDA Approves Puma Biotechnology’s Extended Adjuvant Therapy for Breast

July 19, 2017 - Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) has been approved by the US Food and Drug Administration (FDA).

Featured In: Biotech News

CAR-T Cell Therapy Shows Promise as Leukemia Treatment in Early Stage Clinical Trial

July 19, 2017 - About 70 percent of clinical trial participants with chronic lymphocytic leukemia experienced tumor shrinkage after being treated with CAR-T immunotherapy, according to researchers at Fred Hutchinson Cancer Research Center.

Featured In: Clinical Trial News


Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know


Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned

EDC and eSource: Combined for Better Data and Faster Insights

Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide

How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Copyright © 2016-2017 Honeycomb Worldwide Inc.